Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group

Christopher W. Ryan, Bryan H. Goldman, Primo N Lara, Philip Mack, Tomasz M. Beer, Catherine M. Tangen, Dianne Lemmon, Chong-Xian Pan, Harry A. Drabkin, E. David Crawford

Research output: Contribution to journalArticlepeer-review

146 Scopus citations

Fingerprint

Dive into the research topics of 'Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group'. Together they form a unique fingerprint.

Medicine & Life Sciences